Acanthosis nigricans
☆ AI Dermatology — Free Service
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Et ass heefeg bei fettleibe Leit.
relevance score : -100.0%
ReferencesAcanthosis nigricans ass eng kutan Manifestatioun vun engem Basisdaten Zoustand. Et erschéngt dacks an Hautfalten wéi den Hals, d'Achsel an d'Liewer, ausgesinn wéi velvety donkel Flecken mat onkloer Kanten. Dësen Zoustand ass normalerweis mat Diabetes an Insulinresistenz verbonnen, awer a rare Fäll kann et op Krebs am Kierper weisen. Et kann och optrieden wéinst Hormonproblemer oder vu spezifesche Medikamenter wéi Steroiden a Geburtskondrollpillen.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) ass e gemeinsame Hautzoustand verbonne mat verschiddene Gesondheetsprobleemer wéi Insulinresistenz, Diabetis, Adipositas, bestëmmte Kriibs, hormonell Probleemer a Reaktiounen op Medikamenter. D'Behandlung vun AN konzentréiert sech op d'Behandlung vun den ënnerliegende Gesondheetsproblemer. Am Ufank kontrolléieren d'Dokteren op Unzeeche vum Insulinresistenzsyndrom, wéi Adipositas, héich Cholesterin, héije Blutdrock an Typ‑2‑Diabetis. D'Dokteren verschreiwen dacks topical retinoids als éischt Behandlungswahl, wat d'Hautverdickung hëllefe kann. Wéi och ëmmer, si adresséieren d'Hautdäischterung net komplett. Aner Behandlungsoptiounen (salicylic acid, podophyllin, urea, calcipotriol) erfuerderen och dacks eng lokal Uwendung.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Ursachen
Et tritt typesch bei Individuen ënner 40 Joer op, kann genetesch ierflech sinn an ass mat Adipositas oder Endokrinopathien assoziéiert, sou wéi Hypothyroidismus, Akromegalie, polycystesch Eierstockerkrankheet, insulin‑resistent Diabetes oder Cushings Krankheet.
○ Behandlung – OTC‑Mëttel
#40% urea cream